Topotecan (NSC609699) HCl

For research use only.

Catalog No.S1231 Synonyms: Nogitecan HCl, SKFS 104864A

31 publications

Topotecan (NSC609699) HCl Chemical Structure

CAS No. 119413-54-6

Topotecan HCl (NSC609699, Nogitecan, SKFS 104864A) is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively. Topotecan HCl induces autophagy and apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 230 In stock
USD 180 In stock
USD 320 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Topotecan (NSC609699) HCl has been cited by 31 publications

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Topotecan HCl (NSC609699, Nogitecan, SKFS 104864A) is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively. Topotecan HCl induces autophagy and apoptosis.
Features Topotecan is a water-soluble derivative of camptothecin.
Targets
Topo I (DU-145 Luc cells) [1]
(Cell-free assay)
Topo I (MCF-7 Luc cells) [1]
(Cell-free assay)
2 nM 13 nM
In vitro

Stronger drug activity of Topotecan is observed for DU-145 Luc and MCF-7 Luc cells. [1] Topotecan causes cytotoxicity during the course of DNA replication by stabilizing the covalent complex between topoisomerase I and DNA and preventing the religation of enzyme-linked single-strand DNA break. Topotecan stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage acute lymphoblastic leukemia (ALL) cells, causes rapid apoptotic cell death despite high-level expression of bcl-2 protein, and inhibits ALL cell clonogenic growth in a dose-dependent fashion. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-435 cells NXftZVEzS3m2b4TvfIlkyqCjc4PhfS=> M{nKNFczKGh? NWrKOGE{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ{PSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBq[zVyPUGgcm0> M1zTN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{exNVg{Lz5{MEO3NVE5OzxxYU6=
human Bel7402 cells NFXUc4NEgXSxdH;4bYPDqGG|c3H5 M{fScVk3KGh? M1\TXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJmdDd2MEKgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0yNjJibl2= NIjXNIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUG2OVE1PCd-MUWxOlUyPDR:L3G+
human HCT8 cells MmrQR5l1d3SxeHnjxsBie3OjeR?= MXG5OkBp NVvQNphDS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWODDj[YxteyCjZoTldkA6PiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVEvPSCwTR?= Mlr5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTVzNkWxOFQoRjF3MU[1NVQ1RC:jPh?=
human MCF7 cells NHjtfWxEgXSxdH;4bYPDqGG|c3H5 MnfjPVYhcA>? Mo[5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGuPEBvVQ>? Mke0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTVzNkWxOFQoRjF3MU[1NVQ1RC:jPh?=
human A549 cells M{TvXGN6fG:2b4jpZ:Kh[XO|YYm= NIrTcHA6PiCq MlTvR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUOuNkBvVQ>? M2W4ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MU[1NVQ1Lz5zNUG2OVE1PDxxYU6=
human colon carcinoma SW620 cell MX7DfZRwfG:6aXRCpIF{e2G7 M3K2O2N6fG:2b4jpZ{Bxd3SnboTpZZRqd25ib3[gWI9xd3SnY3HuJEhVWCliYomgeIhmKGOxbYDveY5lKGmwIHj1cYFvKGOxbH;uJINiemOrbn;tZUBUXzZ{MDDj[YxtKGyrbnWsJGlEPTB;Mz6yJI5O MmK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ2MEi3NFcoRjF{NEC4O|A4RC:jPh?=
human MESSA cells M1O0S2N6fG:2b4jpZ:Kh[XO|YYm= NFS4Upg4OiCq NHHrXohEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTVOVQTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUC9OEBvVQ>? M{fMe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{SxOlc1Lz5{MUO0NVY4PDxxYU6=
human BGC823 cells NGT1VmxEgXSxdH;4bYPDqGG|c3H5 NVXobnhHQTZiaB?= NXzV[XZtS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSkeFOEKzJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PC5|IH7N NVjzV4hqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWxOlUyPDRpPkG1NVY2OTR2PD;hQi=>
human Ketr3 cells NWX3W5Y3S3m2b4TvfIlkyqCjc4PhfS=> MYm5OkBp NXrG[oZES3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU2W2ckOgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF01Njlibl2= M4\iS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MU[1NVQ1Lz5zNUG2OVE1PDxxYU6=
LOX cells NFLvRVJEgXSxdH;4bYPDqGG|c3H5 NYC3UFNZS3m2b4TvfIlkcXS7IIfhd{Bl\XSncn3pcoVlKGmwII\peJJwKGmwIFzPXEBk\WyuczCocYVt[W6xbXGpJI9nKGi3bXHuJJR2dW:{IHPlcIwhdGmwZYOgZpkhfXOrbnegUXRVKGG|c3H5MEBKSzVyPUWgcm0> M4jaN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd6NUOzN|EoRjd6NUOzN|E9N2F-
human A549 cells M3fEXGZ2dmO2aX;uJIF{e2G7 NUP5b3ZXPCCq NHT0WWtCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IESgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD13IH7N NWrBVGt4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyNFc4PDhpPkG4NlA4PzR6PD;hQi=>
human H69 cells MV\DfZRwfG:6aXRCpIF{e2G7 NEHGc|c4OiCq NVe4V3UzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUDZ7IHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME22JI5O Mlv3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|NEG2O|QoRjJzM{SxOlc1RC:jPh?=
human A2780 cells NEP1WI1EgXSxdH;4bYPDqGG|c3H5 MkHnO|IhcA>? MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{BwfmW{ZYjwdoV{e2mwZzDhcJBp[TWkZYThN{BqdnSnZ4LpckBie3Onc4Pl[EBieyClZXzsJJN2en[rdnHsJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;NjDuUS=> NGfIUmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm1PVI1Pid-MkK5OVkzPDZ:L3G+
human LNCAP cells M{jIeGN6fG:2b4jpZ:Kh[XO|YYm= MYm3NkBp NEPFd|BEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVkODUDDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUC9PUBvVQ>? M{izWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{SxOlc1Lz5{MUO0NVY4PDxxYU6=
human HOP62 cells MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmPnS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTG9RPjJiY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCLQ{WwQVExKG6P M17hRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUC5Nlc6Lz5{NUmwPVI4QTxxYU6=
human MCF7 cells MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGTyOHJIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIx{KGK7IH\peoUu\G:|ZTDndo94fGhiaX7obYJqfGmxbjDhd5NigSxiSVO1NF0yOCCwTR?= MlnMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MEmyO|koRjJ3OUC5Nlc6RC:jPh?=
human UACC62 cells MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDVRWNEPjJiY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCLQ{WwQVExKG6P MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlyOUK3PUc,OjV7MEmyO|k9N2F-
human DU145 cells MoLxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MljpS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSHUyPDViY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCLQ{WwQVExKG6P NHrqV409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmwPVI4QSd-MkW5NFkzPzl:L3G+
LoVo cell line NXfFSYN[S3m2b4TvfIlkyqCjc4PhfS=> M1K0VWN6fG:2b4jpZ{Bxd3SnboTpZZRqd25ib3[gWI9xd3SnY3HuJEhVWCliYomgeIhmKGOxbYDveY5lKGmwIDjoeY1idiClb3zvdoVkfGGuIHPhcoNmeiCOb2\vJINmdGxibHnu[UwhUUN3ME2xNU43KG6P MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjRyOEewO{c,OTJ2MEi3NFc9N2F-
human lymphoblast tumor cell line RPM18402 NY\KPZBUS3m2b4TvfIlkyqCjc4PhfS=> MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDsfY1xcG:kbHHzeEB1fW2xcjDj[YxtKGyrbnWgVnBOOTh2MEKsJGlEPTB;MUKgcm0> NXPNdXNwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKzPVI4PDVpPkGyN|kzPzR3PD;hQi=>
human HL60 cells MmPFSpVv[3Srb36gZZN{[Xl? NHzvXI1CdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIJ6KFOUQjDt[ZRpd2RuIFnDOVA:OTJibl2= M{fMZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUSxOFg{Lz5zOUW0NVQ5OzxxYU6=
human A375 cells M33oUWN6fG:2b4jpZ:Kh[XO|YYm= M3r1VlczKGh? MmCzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVM4PSClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmsJGlEPTB;MUOgcm0> M2LvOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{SxOlc1Lz5{MUO0NVY4PDxxYU6=
COR-L23/P cell M1z3SmN6fG:2b4jpZ:Kh[XO|YYm= MnjrR5l1d3SxeHnjbZR6KG2nYYP1doVlKHW|aX7nJJRp\SCFT2KtUFI{KHCjcnXueIFtKCiFT2KtUFI{N1BrIHj1cYFvKG6xbjDzcYFtdCClZXzsJIx2dmdiY3HyZ4lvd22jIHPlcIwhdGmwZTygTWM2OD1zMz6yJI5O NH7DZlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUiwOlczPCd-MUG4NFY4OjR:L3G+
human NCI-H460 cells NF3IN2RRem:uaX\ldoF1cW:wIHHzd4F6 NHLNN3Y4OiCq MlTxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFQ3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgZ492dHSncjDjc5VvfGW{IHHuZYx6e2m|LDDJR|UxRTF4IH7N MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd6M{O2PUc,OjF5OEOzOlk9N2F-
human MOLT4 cells NVr1SFhCS3m2b4TvfIlkyqCjc4PhfS=> NF:xe4k4OiCq NEPQbXREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOV0yWNDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVE6KG6P NFzBRXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFczPSd-MkS5NFA4OjV:L3G+
human LoVo cells NXzCdZRCS3m2b4TvfIlkyqCjc4PhfS=> NXjFcYdkPzJiaB?= M{S1NGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxwXm9iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yNEBvVQ>? NIrK[IU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO3NVE5Oyd-MkCzO|EyQDN:L3G+
RPM18402 tumor cell line MXzQdo9tcW[ncnH0bY9vKGG|c3H5 MXvDc45k\W62cnH0bY9vKHKncYXpdoVlKHSxIHnubIljcXRiY3XscEBxem:uaX\ldoF1cW:wIHnuJHJRVTF6NECyJJR2dW:{IHPlcIwhdGmwZTygTWM2OD1{MDDuUS=> NVfRXWpPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW0PFI6OjlpPkG1OFgzQTJ7PD;hQi=>
human SN12C cells M3;mb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEHT[3ZIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUVjF{QzDj[YxteyCkeTDmbZZmNWSxc3Wg[5Jwf3SqIHnubIljcXSrb36gZZN{[XluIFfJOVA:OjBibl2= MoWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MEmyO|koRjJ3OUC5Nlc6RC:jPh?=
human RPMI8226 cells NXP0bIt4S3m2b4TvfIlkyqCjc4PhfS=> M{CyVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHJRVUl6MkK2JINmdGy|IHL5JG1VXCCvZYToc4QtKEmFNUC9NlEhdk1? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTBzMkm5Okc,OTlyMUK5PVY9N2F-
HT-29 cells NYLGeHhTS3m2b4TvfIlkyqCjc4PhfS=> NUfaNWs5S3m2b4TvfIlkcXS7IIfhd{Bl\XSncn3pcoVlKGmwII\peJJwKGmwIFjUMVI6KGOnbHzzLINwdG:wKTDv[kBpfW2jbjD0eY1weiClZXzsJIxqdmW|IHL5JJV{cW6pIF3UWEBie3OjeTygTWM2OD1{NTDuUS=> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek84QDV|M{OxK|44QDV|M{OxQE9iRg>?
SK-BR-3 cells M4jwZ2N6fG:2b4jpZ:Kh[XO|YYm= MVLJckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDidoVie3RiY3HuZ4VzKGOnbHygcIlv\SBqU1utRnIuOyluIFnDOVA:OjZibl2= NETnd5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN|Q2Pjl:L3G+
HeLa cells NILSbo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmXLS5Jwf3SqIHnubIljcXSrb36gc4YhUGWOYTDj[YxteyCjZoTldkA1KGSjeYOsJGdKPTB;M{Cgcm0> MnrvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2MUi1PFIoRjF5NEG4OVgzRC:jPh?=
UACC 62 cells MnHSR5l1d3SxeHnjxsBie3OjeR?= NVPDXVE4XGW|dHXkJIlvKH[rdILvJIZweiCleYTveI95cWOrdImgZYdicW6|dDDoeY1idiC2dX3vdkBk\WyuIHzpcoUhXUGFQzC2NkApdWWuYX7vcYEqNCCJSUWwQVMxKG6P MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODdzNEWwNkc,OTB5MUS1NFI9N2F-
human HCT116 cells M13NOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnLDS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KGK7IH\peoUu\G:|ZTDndo94fGhiaX7obYJqfGmxbjDhd5NigSxiR1m1NF0{OCCwTR?= NV3EcoRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NFkzPzlpPkK1PVA6Ojd7PD;hQi=>
human lung cancer cell line (H128) M4DY[2N6fG:2b4jpZ:Kh[XO|YYm= M2TZdmlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIx2dmdiY3HuZ4VzKGOnbHygcIlv\SBqSEGyPEktKEmFNUC9N|Ehdk1? M4LxXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{O0OVY6Lz5zMUOzOFU3QTxxYU6=
human MES-SA/Dx5 cells M1zOUWN6fG:2b4jpZ:Kh[XO|YYm= NFHmWnFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTVNvU1GvSJg2KGOnbHzzJI93\XKneIDy[ZN{cW6pIF3EVlEh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyPUOzJI5O MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN2MU[3OEc,OjF|NEG2O|Q9N2F-
human A2780 cells MVjDfZRwfG:6aXRCpIF{e2G7 NFnLPWE4OiCq MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUOzJI5O MnHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3NlUoRjJ2OUCwO|I2RC:jPh?=
human MDA-MB-435 cells MnXrR5l1d3SxeHnjxsBie3OjeR?= MV:3NkBp Mn;ER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUSzOUBk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCPVGSgZZN{[XluIFfJOVA:OzRibl2= NGHMeIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mki2O|AyQSd-MkK4OlcxOTl:L3G+
human stomach cancer cell line (MKN45) NHTSU29EgXSxdH;4bYPDqGG|c3H5 NX7MbZpYUW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4he3SxbXHjbEBk[W6lZYKgZ4VtdCCuaX7lJEhOU052NTmsJGlEPTB;M{igcm0> MnPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF|M{S1OlkoRjFzM{O0OVY6RC:jPh?=
human KB3-1 cells MXnDfZRwfG:6aXRCpIF{e2G7 MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRlMuOSClZXzsd{Bi\nSncjDNWHQh[XO|YYmsJGlEPTB;NECgcm0> M2XIZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OEK5N|M1Lz5zOEiyPVM{PDxxYU6=
mouse P388 cells NIf4Z2NEgXSxdH;4bYPDqGG|c3H5 Ml3QR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgVFM5QCClZXzsd{Bi\nSncjDNWHQh[XO|YYmsJGlEPTB;NEWgcm0> NXT2PWNJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4Nlk{OzRpPkG4PFI6OzN2PD;hQi=>
A427 human lung carcinoma NVfsS5ZCWHKxbHnm[ZJifGmxbjDhd5NigQ>? MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDt[YF{fXKnZDDh[4FqdnO2IFG0NlchcHWvYX6gcJVv\yClYYLjbY5wdWFuIFnDOVA:PDlibl2= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86QDd4MUGxK|46QDd4MUGxQE9iRg>?
human U251 cells Mn:5SpVv[3Srb36gZZN{[Xl? NFLZRpE3NTJ2IHi= NIjpOYxKdmirYnn0bY9vKG:oIITvdI9qe2:vZYLhd4UuOSCrbjDoeY1idiCXMkWxJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiaInwc5hq[S2rbnT1Z4VlKEiLRj2xZYxxcGFiYXPjeY12dGG2aX;uJIlvKG63Y3zlZZIh\Xi2cnHjeEBi\nSncjC2JJRwKDJ2IHjyd{BjgSCrbX31co9jdG:2IHHuZYx6e2m|LDDFR|UxRTV2IH7N MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjNyNU[xNkc,OjJ|MEW2NVI9N2F-
human colon cancer cell line (WiDr) NInRdZJEgXSxdH;4bYPDqGG|c3H5 MoC0TY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHygcIlv\SBqV3nEdkktKEmFNUC9OVYhdk1? M1HufVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{O0OVY6Lz5zMUOzOFU3QTxxYU6=
human HepG2 cells MXjDfZRwfG:6aXRCpIF{e2G7 NWfMOmxVPCCmYYnz M3HGO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGGodHXyJFQh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9OlAhdk1? NVvIT|ZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OVQ6ODZpPkG4OVU1QTB4PD;hQi=>
human KB cells M1KxT2N6fG:2b4jpZ:Kh[XO|YYm= NF7BfYM4OiCq MV3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB5MjDodpMhe3WuZn;ybI9l[W2rbnWgRkBkd2yxcnnt[ZRzcWNiYYPzZZktKEmFNUC9OlIvPSCwTR?= M3LWVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC4OFU3Lz5{NUCwPFQ2PjxxYU6=
human HCT8 cells NF34WohEgXSxdH;4bYPDqGG|c3H5 NHzUTGc{KGSjeYO= MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3Q5KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHQh[XO|YYmsJGlEPTB;N{Cgcm0> NV;hfHY2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzPVI2PDVpPkKwN|kzPTR3PD;hQi=>
human GBM2 cells MYLQdo9tcW[ncnH0bY9vKGG|c3H5 Ml\3O|IhcA>? NELaeWlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFfCUVIh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JHdUXC1zIH3leIhw\CxiSVO1NF0xNjF|IN88US=> M3;nO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{W1OVMzLz5{NkO1OVU{OjxxYU6=
SK-MEL-2 cells MXfDfZRwfG:6aXRCpIF{e2G7 NHXaRoQ4OiCq NIrBOnVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2PRVytNkBk\WyuczDh[pRmeiB5MjDodpMh[nliYXzhcYFzKGKudXWgZZN{[XluIFnDOVA:OC5zNDFOwG0> MnfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|NEG2O|QoRjJzM{SxOlc1RC:jPh?=
human IGROV1 cells NWj2cHI6S3m2b4TvfIlkyqCjc4PhfS=> MXW3NkBp NYTmTFdyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUUeUT2[xJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiSVO1NF0xNjF4IN88US=> MnnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|NEG2O|QoRjJzM{SxOlc1RC:jPh?=
human U87 cells MoP6VJJwdGmoZYLheIlwdiCjc4PhfS=> M3fvb|Q5KGh? NV3ZZ2I1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFch[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgOFghcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlE3KM7:TR?= M2jsNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEK2PFE5Lz5{NEiyOlgyQDxxYU6=
human HT1080 cells NVrYXWEyWHKxbHnm[ZJifGmxbjDhd5NigQ>? MkXoOFghcA>? M1Lh[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGSxNFgxKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFnDOVA:OC5zODFOwG0> MlvwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2MEi4NVUoRjJ4NEC4PFE2RC:jPh?=
human Hep3B cells NYnGdZVDWHKxbHnm[ZJifGmxbjDhd5NigQ>? M3nWN|czKGh? M{fYRmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwN2Ih[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGjUWEBie3OjeTygS2k2OD1yLkKyJO69VQ>? MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd7Nkm1Okc,OTl5OU[5OVY9N2F-
human GBM3 cells NIHRdFZRem:uaX\ldoF1cW:wIHHzd4F6 NVXP[FhDPzJiaB?= NUja[205SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDHRm0{KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBYW1RvMTDt[ZRpd2RuIFnDOVA:OC5|ODFOwG0> MmiyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NUW1N|IoRjJ4M{W1OVMzRC:jPh?=
human KBVIN cells NF7ldpJEgXSxdH;4bYPDqGG|c3H5 MXi3NkBp MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRnZKViClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG|c3H5MEBKSzVyPUCuOEDPxE1? M1foUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEO4O|Y6Lz5{NUSzPFc3QTxxYU6=
human GBM1 cells MYjQdo9tcW[ncnH0bY9vKGG|c3H5 NVT2U3d[PzJiaB?= NX\u[oQ5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDHRm0yKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBYW1RvMTDt[ZRpd2RuIFnDOVA:OC52NjFOwG0> M{\scVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{W1OVMzLz5{NkO1OVU{OjxxYU6=
human U937 cells NWP4bGdLS3m2b4TvfIlkyqCjc4PhfS=> MWm0PEBp NGK4OotEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWQTN5IHPlcIx{KGW6cILld5NqdmdicEWzJI12fGGwdDDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7IP-8kEBKSzVyPUGuNUDPxE1? M1vCPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{G1N|E6Lz5zOUexOVMyQTxxYU6=
Caco2 NF\z[pFEgXSxdH;4bYNqfHliYYPzZZk> NE\kbZIzPCCqcoO= M3uz[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNi[29{IHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4yOToQvF2u MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl6MEGxPEc,OjR7OECxNVg9N2F-
Jurkat NUG1fVRRS3m2b4TvfIlkcXS7IHHzd4F6 MWCyOEBpenN? NXvYNZoxS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUnW{a3H0JINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5zMkhOwG0v NWDpWXdGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PFAyOThpPkK0PVgxOTF6PD;hQi=>
A375 MYPDfZRwfG:6aXPpeJkh[XO|YYm= MViyOEBpenN? M36zfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE{PzViY3XscJMh[W[2ZYKgNlQhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlE3Os7:TT6= M2rreVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUiwNVE5Lz5{NEm4NFEyQDxxYU6=
HeLa Mlq5R5l1d3SxeHnjbZR6KGG|c3H5 NFnRXZYzPCCqcoO= MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6zPO69VS5? M3LCTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUiwNVE5Lz5{NEm4NFEyQDxxYU6=
MDA-MB-231 MlriR5l1d3SxeHnjbZR6KGG|c3H5 M2Cze|I1KGi{cx?= M{T0WGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkS3N:69VS5? M1jQSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUiwNVE5Lz5{NEm4NFEyQDxxYU6=
NCI-H460 MnTBRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NFHJeWEyKGi{ NGH4[oFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPDZyIHPlcIx{KGGodHXyJJNpd3K2IITldo0h\Xiyb4P1doUh\m:{IEGgbJIhdWWjc4Xy[YQh[W[2ZYKgO|IhcHK|IHnuJIRzfWdvZoLl[UBu\WSrdX2sJGlEPTB;MD62Ne69VS5? M2PrWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUOwO|IxLz5zOUWzNFczODxxYU6=
HCT8 NVTCWow3SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NHTDPWo1QCCqcoO= NVLSXZFtSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3Q5KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDDR2s5KGG|c3H5MEBKSzVyPUGuPFc2|ryPLh?= MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR6MUO5OUc,OjV2OEGzPVU9N2F-
KB Mo\RRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MUG0PEBpenN? MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEuEIHPlcIx{KGGodHXyJFQ5KGi{czDifUBES0t6IHHzd4F6NCCLQ{WwQVIvOjh{zszNMi=> M{nk[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEixN|k2Lz5{NUS4NVM6PTxxYU6=
SGC7901 NHTQe|FCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MmrIOFghcHK| NGTHSnRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPHR|c6ODFiY3XscJMh[W[2ZYKgOFghcHK|IHL5JGNEUzhiYYPzZZktKEmFNUC9Nk4zQTMQvF2u NUTEdWlvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0PFE{QTVpPkK1OFgyOzl3PD;hQi=>
HepG2 MYTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NFLGcXA1QCCqcoO= NGrPSZhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDDR2s5KGG|c3H5MEBKSzVyPUSuNlA5|ryPLh?= NGXnSok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS4NVM6PSd-MkW0PFE{QTV:L3G+
MDA-MB-231 M3jWPGFxd3C2b4Ppd{Bie3OjeR?= M2O3cmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTVTBMW1DNTJ|MTDj[YxteyCjc4Pld5Nm\CCjczDwOVMheGixc4Doc5J6dGG2aX;uJIF1KFOnckG1JIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl6MEGxPEc,OjR7OECxNVg9N2F-
HeLa MYDBdI9xfG:|aYOgZZN{[Xl? NGruNVMxNjhidH:gNU43KHWP MoLWNlQhcHK| NUGwXoFyUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDI[WxiKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gSG5CKHO7boTo[ZNqeyCjdDCwMlghfG9iMT62JJVOKGGodHXyJFI1KGi{czDifUBDemSXIIP0ZYlvcW6pLXLhd4VlKEWOSWPB NUjnXXB4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PFAyOThpPkK0PVgxOTF6PD;hQi=>
MDA-MB-231 MWPBdI9xfG:|aYOgZZN{[Xl? M1XHUlAvQCC2bzCxMlYhfU1? Mkn6NlQhcHK| MmXOTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhTE6DIIP5cpRp\XOrczDheEAxNjhidH:gNU43KHWPIHHmeIVzKDJ2IHjyd{BjgSCEcnTVJJN1[WmwaX7nMYJie2WmIFXMTXNC MlTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OECxNVgoRjJ2OUiwNVE5RC:jPh?=
A375 NFXoNW5CeG:ydH;zbZMh[XO|YYm= M3LmVVAvQCC2bzCxMlYhfU1? MnTLNlQhcHK| M37vZWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iQUO3OUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFTORUB{gW62aHXzbZMh[XRiMD64JJRwKDFwNjD1UUBi\nSncjCyOEBpenNiYomgRpJlXSC|dHHpcolv\y2kYYPl[EBGVEmVQR?= NIrJ[2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm4NFEyQCd-MkS5PFAyOTh:L3G+
Caco2 NHjYeYhCeG:ydH;zbZMh[XO|YYm= NFj3UWcxNjhidH:gNU43KHWP NHSxepkzPCCqcoO= NU[0OlA5UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDDZYNwOiClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGRPSSC|eX70bIV{cXNiYYSgNE45KHSxIEGuOkB2VSCjZoTldkAzPCCqcoOgZpkhSnKmVTDzeIFqdmmwZz3iZZNm\CCHTFnTRS=> MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl6MEGxPEc,OjR7OECxNVg9N2F-
A375 NWXlc291SXCxcITvd4l{KGG|c3H5 M1Psc2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iQUO3OUBk\WyuczDhd5Nme3OnZDDhd{BxPTNicHjvd5Bpd3K7bHH0bY9vKGG2IGPldlE2KGK7IGfld5Rmem5iYnzveJRqdmdiYX7hcJl{cXN? M3v4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUiwNVE5Lz5{NEm4NFEyQDxxYU6=
TC32 M2LxdZFJXFNiYYPzZZk> M{DWVZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy| MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
DAOY MV3xTHRUKGG|c3H5 NHrjdoNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?= NV2xfo16RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 NY\4VWlEeUiWUzDhd5NigQ>? MmrMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= M1z4NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 MkH3dWhVWyCjc4PhfS=> MkLpdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? MlG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC M3PUWpFJXFNiYYPzZZk> NWjQTXpLeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> MlXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 Mn;tdWhVWyCjc4PhfS=> NYnvUJNueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz M3z4ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 MmP1dWhVWyCjc4PhfS=> NUTUOJZveUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CMWVD[zFiY3XscJM> MmHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 MnjNdWhVWyCjc4PhfS=> MoPxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH NIj3V5VyUFSVIHHzd4F6 Mn3xdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= NXHieJpvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 MlXzdWhVWyCjc4PhfS=> MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| NF;ibpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
LAN-5 MkHndWhVWyCjc4PhfS=> NYPx[5RSeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-12 M1i1UpFJXFNiYYPzZZk> MnjLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy| NU\W[HJORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18 MlS3dWhVWyCjc4PhfS=> MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? NFrvcWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 M3;MTpFJXFNiYYPzZZk> NIfsdZlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz Ml;EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD NWXwOmZXeUiWUzDhd5NigQ>? M4qwR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? M3;YTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) MVvxTHRUKGG|c3H5 M3nwN5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= M4X2RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 NW\mPJAyeUiWUzDhd5NigQ>? Mn21dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? NFLJbmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 MnjWdWhVWyCjc4PhfS=> MmD1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIyPjR|IHPlcIx{ MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
A673 MYrxTHRUKGG|c3H5 NEfpNXJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd|IHPlcIx{MQ>? NYXBeWJ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC NH36VW5yUFSVIHHzd4F6 NWO5XlRyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= M4PmcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 M2X0TJFJXFNiYYPzZZk> NVnxOGJpeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? M3X1ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 M1PVfZFJXFNiYYPzZZk> MoLydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUGFPNTViY3XscJM> MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
DAOY NHOxOZJyUFSVIHHzd4F6 NHvLdpdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBFSU:\IHPlcIx{ NHnjRpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 NVHUXJF6eUiWUzDhd5NigQ>? Mne1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIuTUKlMTDj[Yxtew>? NEe4RlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 M1HzS5FJXFNiYYPzZZk> M1nFTZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNLNUeETUKgZ4VtdHN? MmXUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 NE\o[m5yUFSVIHHzd4F6 M123UpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTN5IHPlcIx{ Mne3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
TC32 M3PMbJFJXFNiYYPzZZk> NWPmTVd2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN|MjDj[Yxtew>? NVXZOmNwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R) M{PpVpFJXFNiYYPzZZk> NE\xeHRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>? NX\jVolGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS M3vwN5FJXFNiYYPzZZk> NXnE[lNyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy| MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 MYHxTHRUKGG|c3H5 MlvydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=> M{jMS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD NV\kXIpVeUiWUzDhd5NigQ>? NXjRV49reUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWkRiY3XscJM> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh18 M2O4[5FJXFNiYYPzZZk> MmfNdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVogyQCClZXzsdy=> NGTOXos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 MkLXdWhVWyCjc4PhfS=> NHznVZJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDNyIHPlcIx{ NH23[3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 MmTpdWhVWyCjc4PhfS=> MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTZY9{NTJiY3XscJM> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 NWjpelh1eUiWUzDhd5NigQ>? M17LepFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG9JWy13MDDj[Yxtew>? NEG4[Ic9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH NUXNWYhbeUiWUzDhd5NigQ>? NIPPRXNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy| NVrwSo41RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH NUXZdGlDeUiWUzDhd5NigQ>? NHn2SldyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= M{LQRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 M1nsV5FJXFNiYYPzZZk> M{G0TpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1Sgeoli[mmuaYT5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= Mn7iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Daoy Mnf4dWhVWyCjc4PhfS=> MlTtdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohV3K2aH;nc45idCB|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBF[W:7IHPlcIx{ MljUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
TC32 NWmxXmNOeUiWUzDhd5NigQ>? NW\YXWZOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEBk[XOyYYPlJJNkemWnbjDmc5IhXEN|MjDj[Yxtew>? NV:xU3NjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32 Ml3zdWhVWyCjc4PhfS=> MYHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) MWPxTHRUKGG|c3H5 NYOwO5lMeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD MUPxTHRUKGG|c3H5 NV;odGtmeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCURDDj[Yxtew>? MoTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LC3 / p62 ; 

PubMed: 23024792     


The indicated cells were treated with the indicated concentrations of topotecan for 24 h. The lysates were analysed by immunoblotting with The LC3 and P62 antibodies.

p53 / sesn2 / p-AMPK ; 

PubMed: 23024792     


HCT116 and LS-174T cells were treated with various concentrations of TPT for 24 h. The levels of P53, sestrin2 and p-AMPK were analysed by immunoblotting. 

23024792
Growth inhibition assay
Cell viability ; 

PubMed: 28544814     


Dose-response curves for topotecan (panel A) were determined in neuroblastoma cell lines The IC50 for the drugs are indicated. Changes in LAN-1 cell viablity as a function of different topotecan exposure times (panel B) were determined.

28544814
In vivo Animals inoculate s.c. with DU-145 Luc cells and then treated with Topotecan demonstrates significant tumor growth and regression as measured with calipers and luminescent imaging. The correlation coefficient is 0.75 for the control untreated group and 0.93 for the Topotecan-treated group. Similarly, tumor progression and regression are measurable using luminescent imaging for untreated and Topotecan-treated mice inoculated i.p. with MCF-7 Luc cells. [1] Topotecan elicited potent antileukemic activity in severe combined immune-deficiency (SCID) mouse models of human poor prognosis ALL. Topotecan markedly improved event-free survival of SCID mice challenged with otherwise fatal doses of humaln leukemia cells at systemic drug exposure levels. [2] Gliomas preferentially express TRAIL R2 and that treatment with Topotecan significantly up-regulates its expression. [3]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: MCF-7 Luc and DU-145 Luc cells
  • Concentrations: 0 μg/mL - 0.692 μg/mL
  • Incubation Time: 96 hours
  • Method:

    Topotecan is dissolved in sterile water to a stock concentration of 1 mg/mL, diluted to 6 μg/mL in cultured medium and then serially diluted 1:4 in opaque, white tissue culture-treated microplates to a final volume of 0.1 mL/well. MCF-7 Luc and DU-145 Luc cells are resuspended in 3×104 cells/mL in DMEM with high glucose containing 10% FBS and 0.5 mg/mL Geneticin; 100 μL of cells are added in each well. Plates are incubated for 4 days at 37 °C in 95% humidity/5% CO2. After incubation, 0.05 mL of 0.1 M HEPES buffer (pH 7.9) containing 50 μg/mL D-luciferin is added to each well. After incubation at room temperature for 10 minutes, the culture microplate is measured in a microplate luminometer and a molecular light imager. Results obtained with the microplate luminometer are calculated using no inhibition control wells without exogenous drug and maximum inhibition control wells containing ATP inhibitor. Results for the molecular light imager are similarly calculated using values obtained with a 5 minutes luminescent imager.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Mice with MCF-7 Luc or DU-145 Luc cells
  • Dosages: 0.25 mg/mL
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL (198.72 mM)
Water 91 mg/mL (198.72 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 457.91
Formula

C23H23N3O5.HCl

CAS No. 119413-54-6
Storage powder
in solvent
Synonyms Nogitecan HCl, SKFS 104864A
Smiles CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04455139 Not yet recruiting Drug: Topotecan|Drug: Melphalan Eye Cancer Retinoblastoma Prof. Beck Popovic Maja|University of Lausanne Hospitals June 1 2021 Phase 2
NCT04428879 Recruiting Drug: Topotecan Episcleral Plaque Retinoblastoma The Hospital for Sick Children June 16 2020 Phase 1
NCT04156347 Not yet recruiting Drug: Episcleral Topotecan Retinoblastoma Targeted Therapy Technologies LLC April 1 2020 Phase 1
NCT04022876 Recruiting Drug: ALRN-6924|Drug: Topotecan Small-cell Lung Cancer Aileron Therapeutics September 3 2019 Phase 1|Phase 2
NCT03927274 Recruiting Drug: Topotecan Glioma of Brain H. Lee Moffitt Cancer Center and Research Institute June 20 2019 Early Phase 1
NCT03600649 Recruiting Drug: Seclidemstat|Drug: Cyclophosphamide|Drug: Topotecan Ewing Sarcoma Salarius Pharmaceuticals LLC|National Pediatric Cancer Foundation June 4 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like get the compound for mice intraperitoneally injection, What would you recommend to improve solubility? What could I use as solvent (%v?) that is nontoxic (unlike Methanol) and could be injected into mice intraperitoneally?

  • Answer:

    Topotecan HCl is generally prepared by Saline for I.P. administration.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Topotecan (NSC609699) HCl | Topotecan (NSC609699) HCl supplier | purchase Topotecan (NSC609699) HCl | Topotecan (NSC609699) HCl cost | Topotecan (NSC609699) HCl manufacturer | order Topotecan (NSC609699) HCl | Topotecan (NSC609699) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID